The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model.
Arthritis Rheum. 2001 Jun;44(6):1293-303. doi: 10.1002/1529-0131(200106)44:6<1293::AID-ART221>3.0.CO;2-T.
Arthritis Rheum. 2001.
PMID: 11407688
Free article.